

# CITATION REPORT

List of articles citing

## The neuropathological effects of antipsychotic drugs

DOI: 10.1016/s0920-9964(99)00065-1  
Schizophrenia Research, 1999, 40, 87-99.

**Source:** <https://exaly.com/paper-pdf/30860968/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
136	Synaptophysin gene expression in schizophrenia. Investigation of synaptic pathology in the cerebral cortex. <b>2000</b> , 176, 236-42		81
135	Expression of complexin I and II mRNAs and their regulation by antipsychotic drugs in the rat forebrain. <b>2000</b> , 36, 167-77		38
134	Hippocampal synaptic pathology in schizophrenia, bipolar disorder and major depression: a study of complexin mRNAs. <i>Molecular Psychiatry</i> , <b>2000</b> , 5, 425-32	15.1	147
133	Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. <b>2001</b> , 50, 729-42		157
132	Gray matter-changes and correlates of disease severity in schizophrenia: a statistical parametric mapping study. <b>2001</b> , 13, 814-24		131
131	Cerebellar synaptic protein expression in schizophrenia. <b>2001</b> , 105, 219-29		99
130	Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a Western blot study of synaptophysin, GAP-43 and the complexins. <b>2001</b> , 55, 569-78		229
129	Cholinergic systems and schizophrenia: primary pathology or epiphenomena?. <b>2001</b> , 22, 53-63		99
128	Current World Literature. <b>2001</b> , 14, 65-101		
127	Short and long term effects of antipsychotic medication on smooth pursuit eye tracking in schizophrenia. <b>2001</b> , 157, 284-91		29
126	Amygdalar activation alters the hippocampal GABA system: "partial" modelling for postmortem changes in schizophrenia. <b>2001</b> , 431, 129-38		81
125	Neuropathological studies of synaptic connectivity in the hippocampal formation in schizophrenia. <b>2001</b> , 11, 508-19		186
124	Neuropathological abnormalities in schizophrenia: evidence from magnetization transfer imaging. <b>2001</b> , 124, 882-92		121
123	Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. <i>American Journal of Psychiatry</i> , <b>2001</b> , 158, 918-25	11.9	173
122	Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. <b>2002</b> , 59, 1002-10		327
121	The neuropathology of primary mood disorder. <b>2002</b> , 125, 1428-49		258
120	Abnormalities of SNARE mechanism proteins in anterior frontal cortex in severe mental illness. <b>2002</b> , 12, 349-56		117

119	Research on the Drug Treatment of Schizophrenia. <b>2002</b> , 38, 217-239		19
118	Reduction of chromogranin B-like immunoreactivity in distinct subregions of the hippocampus from individuals with schizophrenia. <i>Schizophrenia Research</i> , <b>2002</b> , 58, 43-53	3.6	33
117	Acute administration of haloperidol induces apoptosis of neurones in the striatum and substantia nigra in the rat. <b>2002</b> , 109, 89-99		47
116	Iontophoresis of lithium antagonizes noradrenergic action on prefrontal neurons of the rat. <b>2002</b> , 947, 150-6		7
115	Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. <b>2002</b> , 45, 78-85		19
114	The axonal chemorepellant semaphorin 3A is increased in the cerebellum in schizophrenia and may contribute to its synaptic pathology. <i>Molecular Psychiatry</i> , <b>2003</b> , 8, 148-55	15.1	115
113	Presynaptic proteins in the prefrontal cortex of patients with schizophrenia and rats with abnormal prefrontal development. <i>Molecular Psychiatry</i> , <b>2003</b> , 8, 797-810	15.1	104
112	Interstitial white matter neurons express less reelin and are abnormally distributed in schizophrenia: towards an integration of molecular and morphologic aspects of the neurodevelopmental hypothesis. <i>Molecular Psychiatry</i> , <b>2003</b> , 8, 821-831	15.1	166
111	Meta-analysis of brain weight in schizophrenia. <i>Schizophrenia Research</i> , <b>2003</b> , 64, 25-34	3.6	60
110	Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia: a proton magnetic resonance spectroscopy study. <i>Schizophrenia Research</i> , <b>2003</b> , 64, 63-71	3.6	62
109	Chronic schizophrenia as a brain misconnection syndrome: a white matter voxel-based morphometry study. <i>Schizophrenia Research</i> , <b>2003</b> , 64, 15-23	3.6	57
108	Eicosapentaenoic acid in the treatment of schizophrenia and depression: rationale and preliminary double-blind clinical trial results. <b>2003</b> , 69, 477-85		72
107	Children in clinical research: a conflict of moral values. <b>2003</b> , 3, W-IF 2		11
106	The neuropathology of mood disorders. <b>2003</b> , 291-307		1
105	New antipsychotics and schizophrenia: a review on efficacy and side effects. <b>2004</b> , 11, 343-58		87
104	A study of bipolar disorder using magnetization transfer imaging and voxel-based morphometry. <b>2004</b> , 127, 2433-40		92
103	Abnormalities of presynaptic protein CDCrel-1 in striatum of rats reared in social isolation: relevance to neural connectivity in schizophrenia. <b>2004</b> , 20, 303-7		52
102	Decreased cortical gray and cerebral white matter in male patients with familial bipolar I disorder. <b>2004</b> , 82, 475-85		35

101	[Mrt-based morphometry. A current assessment]. <b>2004</b> , 75, 1172-8		3
100	[Changes in brain structure caused by neuroleptic medication]. <b>2004</b> , 75, 1112-7		12
99	Neuroleptic dysphoria: towards a new synthesis. <b>2004</b> , 171, 121-32		90
98	The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. <b>2004</b> , 174, 151-62		510
97	Antipsychotics increase microtubule-associated protein 2 mRNA but not spinophilin mRNA in rat hippocampus and cortex. <b>2004</b> , 76, 376-82		23
96	Effect of haloperidol on the numeric density of neurons and nuclear height in the rat hippocampus: A stereological and histopathological study. <b>2004</b> , 34, 1-9		18
95	Treatment of rats with antipsychotic drugs: lack of an effect on brain N-acetyl aspartate levels. <i>Schizophrenia Research</i> , <b>2004</b> , 66, 31-9	3.6	23
94	Prefrontal cortical thickness in first-episode psychosis: a magnetic resonance imaging study. <b>2004</b> , 55, 131-40		64
93	Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. <b>2004</b> , 28, 1099-107		33
92	Chronic haloperidol or clozapine treatment does not alter parvalbumin immunoreactivity in the rat frontal cortex or hippocampus. <b>2005</b> , 373, 57-60		10
91	Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways. <b>2005</b> , 27, 43-64		90
90	A pathophysiological paradigm for the therapy of psychiatric disease. <b>2005</b> , 4, 467-76		55
89	Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. <i>Molecular Psychiatry</i> , <b>2005</b> , 10, 40-68; image 5	15.1	1654
88	Morphological alterations produced by zinc deficiency in rat sciatic nerve: a histological, electron microscopic, and stereological study. <b>2005</b> , 1048, 228-34		28
87	Neuropathology of schizophrenia. <b>2005</b> , 4, 18-21		5
86	Dopamine specifically inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs. <b>2005</b> , 25, 5815-23		171
85	Insular cortex abnormalities in schizophrenia: Relationship to symptoms and typical neuroleptic exposure. <b>2005</b> , 57, 394-8		52
84	Decreased expression of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia: further evidence for a synaptic pathology affecting glutamate neurons. <i>Schizophrenia Research</i> , <b>2005</b> , 73, 159-72	3.6	154

83	Increased N-acetylaspartate in rat striatum following long-term administration of haloperidol. <i>Schizophrenia Research</i> , <b>2005</b> , 75, 303-8	3.6	46
82	Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia. <i>Schizophrenia Research</i> , <b>2005</b> , 80, 61-71	3.6	86
81	Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. <b>2006</b> , 20, 389-409		315
80	Antipsychotic-associated neuronal changes in the brain: toxic, therapeutic, or irrelevant to the long-term outcome of schizophrenia?. <b>2006</b> , 30, 174-89		38
79	Effects of antipsychotics on brain structure. <b>2006</b> , 19, 145-50		160
78	Rat modeling for GABA defects in schizophrenia. <b>2006</b> , 54, 73-93		3
77	Onset and progression of dystonia in complex regional pain syndrome. <b>2007</b> , 130, 287-293		91
76	Assessment of malondialdehyde levels in schizophrenia: a meta-analysis and some methodological considerations. <b>2007</b> , 31, 365-9		47
75	Effects of alcohol consumption and antipsychotic medication on brain morphology in schizophrenia. <i>Schizophrenia Research</i> , <b>2007</b> , 90, 52-61	3.6	25
74	Nervous System and Special Sense Organs. <b>2007</b> , 861-933		6
73	Cortical thinning in obsessive compulsive disorder. <i>Human Brain Mapping</i> , <b>2007</b> , 28, 1128-35	5.9	46
72	Schizophrenia--a parametersRgame?. <b>2008</b> , 254, 89-98		9
71	Molecular mechanisms of L-DOPA-induced dyskinesia. <b>2008</b> , 9, 665-77		391
70	Neuropathology of schizophrenia. <b>2008</b> , 7, 421-424		6
69	Regional thinning of the cerebral cortex in schizophrenia: effects of diagnosis, age and antipsychotic medication. <i>Schizophrenia Research</i> , <b>2008</b> , 98, 16-28	3.6	161
68	A systematic review of existing data on long-term lithium therapy: neuroprotective or neurotoxic?. <b>2008</b> , 11, 269-87		59
67	Olanzapine, but not haloperidol, enhances PSA-NCAM immunoreactivity in rat prefrontal cortex. <b>2008</b> , 11, 591-5		13
66	Role of the central cholinergic system in the therapeutics of schizophrenia. <b>2008</b> , 6, 286-92		36

65	Increased grey matter densities in schizophrenia patients with negative symptoms after treatment with quetiapine: a voxel-based morphometry study. <b>2009</b> , 24, 34-41		22
64	Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats. <b>2009</b> , 515, 15-30		33
63	Effect of gestational ethanol exposure on parvalbumin and calretinin expressing hippocampal neurons in a chick model of fetal alcohol syndrome. <b>2009</b> , 43, 147-61		7
62	Potential application as screening and drug designing tools of cytoarchitectural deficiencies present in three animal models of schizophrenia. <b>2009</b> , 4, 257-78		5
61	Neurological disorders in schizophrenia. <b>2009</b> , 32, 719-57		21
60	The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia?--a systematic review. <b>2009</b> , 15, 2535-49		182
59	A systematic review of the effects of antipsychotic drugs on brain volume. <i>Psychological Medicine</i> , <b>2010</b> , 40, 1409-22	6.9	234
58	Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. <b>2011</b> , 69, 936-44		139
57	Neuropathology of Schizophrenia. <b>2011</b> , 372-392		4
56	Spreading of complex regional pain syndrome: not a random process. <b>2011</b> , 118, 1301-9		98
55	Typical and atypical neuroleptics. <b>2011</b> , 100, 579-99		13
54	The tardive syndromes. <b>2011</b> , 415-446		3
53	Mitochondria in the striatum of subjects with schizophrenia. <b>2011</b> , 12, 48-56		22
52	Association of Disrupted in Schizophrenia 1 (DISC1) missense variants with ultra-resistant schizophrenia. <b>2011</b> , 11, 267-73		30
51	Nervous System and Special Sense Organs. <b>2012</b> , 799-866		2
50	Potential action of betel alkaloids on positive and negative symptoms of schizophrenia: a review. <b>2012</b> , 66, 73-8		23
49	Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. <i>Molecular Psychiatry</i> , <b>2012</b> , 17, 1206-27	15.1	387
48	Neuropathological changes in the nucleus basalis in schizophrenia. <b>2013</b> , 263, 485-95		24

47	Network dysfunction during associative learning in schizophrenia: Increased activation, but decreased connectivity: an fMRI study. <i>Schizophrenia Research</i> , <b>2013</b> , 148, 38-49	3.6	28
46	α-Lipoic acid interaction with dopamine D2 receptor-dependent activation of the Akt/GSK-3β signaling pathway induced by antipsychotics: potential relevance for the treatment of schizophrenia. <b>2013</b> , 50, 134-45		17
45	NMR-based metabolomics in human disease diagnosis: applications, limitations, and recommendations. <b>2013</b> , 9, 1048-1072		165
44	Disruption of thalamocortical activity in schizophrenia models: relevance to antipsychotic drug action. <b>2013</b> , 16, 2145-63		23
43	Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. <b>2013</b> , 70, 1359-66		107
42	Neurobiological Basis of Dyskinetic Effects Induced by Antipsychotics: the Contribution of Animal Models. <b>2013</b> , 20, 389-396		8
41	Changes in brain functional connectivity after chronic haloperidol in rats: a network analysis. <b>2014</b> , 17, 1129-38		11
40	Implication of the ERK/MAPK pathway in antipsychotics-induced dopamine D2 receptor upregulation and in the preventive effects of (R)-α-lipoic acid in SH-SY5Y neuroblastoma cells. <b>2014</b> , 52, 378-83		7
39	Structural dynamics of dendritic spines: molecular composition, geometry and functional regulation. <b>2014</b> , 1838, 2391-8		27
38	Antipsychotic Drugs. <b>2015</b> , 2088-2128		
37	Tardive syndromes. 61-71		
36	Divergent effects of first-generation and second-generation antipsychotics on cortical thickness in first-episode psychosis. <i>Psychological Medicine</i> , <b>2015</b> , 45, 515-27	6.9	42
35	Hybrid silica monolith for microextraction by packed sorbent to determine drugs from plasma samples by liquid chromatography-tandem mass spectrometry. <i>Talanta</i> , <b>2015</b> , 140, 166-175	6.2	42
34	Understanding schizophrenia as a disorder of consciousness: biological correlates and translational implications from quantum theory perspectives. <i>Clinical Psychopharmacology and Neuroscience</i> , <b>2015</b> , 13, 36-47	3.4	10
33	Antipsychotic medication-induced dysphoria: its meaning, association with typical vs. atypical medications and impact on adherence. <i>Psychiatric Quarterly</i> , <b>2015</b> , 86, 199-205	4.1	10
32	Oxidative and nitrative stress in schizophrenia. <b>2016</b> , 57-76		
31	Effects of Hallucinogens on Neuronal Activity. <i>Current Topics in Behavioral Neurosciences</i> , <b>2018</b> , 36, 75-105	9.4	8
30	Neuroadaptations to antipsychotic drugs: Insights from pre-clinical and human post-mortem studies. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2017</b> , 76, 317-335	9	23

29	The neuropathology of bipolar disorder: systematic review and meta-analysis. <i>Molecular Psychiatry</i> , <b>2020</b> , 25, 1787-1808	15.1	19
28	Evidence for Decreased Density of Calretinin-Immunopositive Neurons in the Caudate Nucleus in Patients With Schizophrenia. <i>Frontiers in Neuroanatomy</i> , <b>2020</b> , 14, 581685	3.6	5
27	Diagnosis- and Cell Type-Specific Mitochondrial Functional Pathway Signatures in Schizophrenia and Bipolar Disorder. <i>American Journal of Psychiatry</i> , <b>2020</b> , 177, 1140-1150	11.9	6
26	The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia. <i>CNS Spectrums</i> , <b>2020</b> , 1-25	1.8	6
25	A meta-analysis of deep brain structural shape and asymmetry abnormalities in 2,833 individuals with schizophrenia compared with 3,929 healthy volunteers via the ENIGMA Consortium. <i>Human Brain Mapping</i> , <b>2021</b> ,	5.9	7
24	Methodological and Stereological Considerations in Postmortem Psychiatric Brain Research. <i>Neurobiological Foundation of Aberrant Behaviors</i> , <b>2002</b> , 21-35		3
23	Oxidative Stress in Schizophrenia. <i>Oxidative Stress in Applied Basic Research and Clinical Practice</i> , <b>2015</b> , 43-72		3
22	Polypharmacy in Schizophrenia. <b>2002</b> , 101-132		3
21	Postmortem studies in schizophrenia. <i>Dialogues in Clinical Neuroscience</i> , <b>2000</b> , 2, 349-57	5.7	32
20	Quantitative Structure-Activity Relationship Study of Some Antipsychotics by Multiple Linear Regressions. <i>American Journal of Analytical Chemistry</i> , <b>2014</b> , 05, 335-342	0.7	1
19	Indications of Abnormal Connectivity in Neuropsychiatric Disorders in Postmortem Studies. <i>Neurobiological Foundation of Aberrant Behaviors</i> , <b>2002</b> , 75-91		
18	Defining the Role of Specific Limbic Circuitry in the Pathophysiology of Schizophrenia and Bipolar Disorder. <i>Neurobiological Foundation of Aberrant Behaviors</i> , <b>2002</b> , 211-233		
17	Schizophrenie. <b>2002</b> , 435-440		
16	The Tardive Syndromes. <b>2007</b> , 479-518		
15	Bildgebende Verfahren. <b>2008</b> , 553-582		
14	What Protects Patients with Schizophrenia from Developing Alzheimer Pathology?. <b>2010</b> , 45-66		1
13	Bildgebende Verfahren. <b>2011</b> , 649-680		
12	The neurobiology of schizophrenia. <b>2012</b> , 561-568		



11 Bildgebende Verfahren in der Psychiatrie. **2016**, 1-36

10 Bildgebende Verfahren in der Psychiatrie. **2017**, 711-746

9 The effect of first- and second-generation antipsychotics on brain morphology in schizophrenia: A systematic review of longitudinal magnetic resonance studies with a randomized allocation to treatment arms.. *Journal of Psychopharmacology*, **2022**, 2698811221087645 4.6 0

8 Image\_1.TIF. **2020**,

7 Image\_2.TIF. **2020**,

6 Image\_3.TIF. **2020**,

5 Image\_4.TIF. **2020**,

4 Image\_5.TIF. **2020**,

3 Image\_6.TIF. **2020**,

2 Image\_7.TIF. **2020**,

1 Table\_1.pdf. **2020**,